<?xml version="1.0" encoding="UTF-8"?>
<p>RDV is actually a prodrug metabolized intracellularly in different human cells [
 <xref rid="B31-jcm-09-02084" ref-type="bibr">31</xref>,
 <xref rid="B60-jcm-09-02084" ref-type="bibr">60</xref>,
 <xref rid="B61-jcm-09-02084" ref-type="bibr">61</xref>] following the subsequent action of various enzymes (esterases and phosphoramidases), and is converted to the monophosphate form of RDV’s active metabolite, GS-441525, which is further phosphorylated by nucleoside-phosphate kinases to its active triphosphate form, interfering with the action of the viral RdRp of Ebola virus via insertion into the newly nascent viral RNA chain and disruption of the virus transcription [
 <xref rid="B61-jcm-09-02084" ref-type="bibr">61</xref>,
 <xref rid="B64-jcm-09-02084" ref-type="bibr">64</xref>,
 <xref rid="B65-jcm-09-02084" ref-type="bibr">65</xref>,
 <xref rid="B66-jcm-09-02084" ref-type="bibr">66</xref>]. RDV exerts a similar mechanism of action in coronaviruses by triggering the inhibition of RdRp complex and the premature termination of the viral RNA chain [
 <xref rid="B31-jcm-09-02084" ref-type="bibr">31</xref>,
 <xref rid="B48-jcm-09-02084" ref-type="bibr">48</xref>]. Moreover, RDV was able to bypass the proofreading 3′-5′ exoribonuclease (ExoN), a unique feature of CoVs, responsible for the decreased activity of various nucleoside analogues used as antivirals [
 <xref rid="B59-jcm-09-02084" ref-type="bibr">59</xref>]. Recent studies identified the architecture of RdRp complex in SARS-CoV-2, the target site for RDV, an important step for a better understanding of the antiviral mechanism of action of RDV in SARS-CoV-2 infection [
 <xref rid="B67-jcm-09-02084" ref-type="bibr">67</xref>,
 <xref rid="B68-jcm-09-02084" ref-type="bibr">68</xref>,
 <xref rid="B69-jcm-09-02084" ref-type="bibr">69</xref>].
</p>
